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Background: Residual and significant post-infarction left ventricular (LV) dysfunction, despite 
technically successful percutaneous coronary intervention (PCI) for ST-elevation myocardial 
infarction (STEMI), remains an important clinical issue. In preclinical models low dose insulin-like 
growth factor 1 (IGF1) has potent cytoprotective and positive cardiac remodelling effects. We 
studied the safety and efficacy of immediate post PCI low dose intracoronary IGF1 infusion in STEMI 
patients. 
 Methods: Using a double-blind, placebo controlled, multi-dose study design, we randomized 47 
STEMI patients with significantly reduced (≤ 40%) LV ejection fraction (LVEF) after successful PCI to 
single intracoronary infusion of placebo (n=15), 1.5ng IGF1 (n=16) or 15ng IGF1 (n=16). All received 
optimal medical therapy. Safety endpoints were freedom from hypoglycaemia, hypotension or 
significant arrhythmias within 1 hour of therapy. The primary efficacy endpoint was LVEF and 
secondary endpoints were LV volumes, mass, stroke volume, and infarct size at 2 months follow up, 
all assessed by MRI. Treatment effects were estimated by analysis of covariance adjusted for 
baseline (24hrs) outcome. 
 Results: No significant differences in safety endpoints occurred between treatment groups out to 30 
days (chi squared test, p-value = 0.77).There were no statistically significant differences in baseline 
(24 hrs post STEMI) clinical characteristics or LVEF among groups. LVEF at 2 months, compared to 
baseline, increased in all groups with no statistically significant differences related to treatment 
assignment. However, compared with placebo or 1.5ng IGF1, treatment with 15ng IGF1 was 
associated with a significant improvement in indexed LV end-diastolic volume (p=0.018), LV mass 
(p=0.004) and stroke volume (p=0.016). Late gadolinium enhancement (±SD) at 2 months was lower 
in 15ng IGF1 (34.5±29.6g) compared to placebo (49.1±19.3g) or 1.5ng IGF1 (47.4±22.4g) treated 
patients, though the result was not statistically significant (p = 0.095). 
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 Conclusion: In this pilot trial, low dose IGF1, given after optimal mechanical reperfusion in STEMI, is 
safe but does not improve LVEF. However, there is a signal for a dose dependent benefit on post MI 
remodeling that may warrant further study. 
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Introduction 
Despite timely reperfusion by primary PCI (PPCI) a significant cohort of patients develop adverse left 
ventricular remodelling with clinical sequelae such as arrhythmia and heart failure[1].Therapeutic 
approaches to avert such remodeling, including a variety of cell therapy and ischemia- reperfusion-
injury mitigation trials have achieved modest success[2,3]. Thus, there remains a significant 
opportunity for novel therapies in this field. 
Conceptually one approach to aid remodeling post large myocardial infarction (MI) would be to 
target early cardiomyocyte death reducing subsequent inflammation, loss of myocardial mass and 
fibrous scar formation post STEMI. Insulin-like growth factor 1 (IGF1) is a potential candidate for 
such a role: it is essential for constitutive cardiomyocyte function and survival[4],has high receptor 
expression in at risk cardiomyocytes post infarction[5], and acts both as a potent inhibitor of cell 
death and a stimulant of resident stem cell mobilization,tissue repair and cardiac remodeling post 
infarction when administered exogenously by diverse delivery approaches[6-10]. However, IGF1 
therapy has never been used in humans post MI predominantly due to previous negative experience 
with high dose studies of human growth hormone in heart failure trials in the mid 1990s [11-14]. 
Due to unproven efficacy and side effects experienced with hGH (which acts via IGF1 in vivo) [14] it 
was presumed that IGF1 would present similar challenges to use in humans and given the presence 
of several IGF binding peptides in the circulation it was also expected that exogenous IGF1 would 
have reduced bioavailability when administered intravenously[8].   
However, IGF1, a small protein, may be ideal for intracoronary delivery into the infarct related artery 
as it exits the permeable coronary microvasculature downstream post-delivery and can act on at risk 
cardiomyocytes within 30 mins of administration as shown by previous receptor-specific signaling in 
pre-clinical studies [5]. In this work single low dose IGF1 given exogenously early after reperfusion 
post MI induced specific activation of the cognate IGF1 receptor and downstream activation of pro-
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survival signaling in at risk cardiomyocytes leading to preservation of LV wall function and marked 
improvement in LV remodeling  in the months post therapy [5]. 
Our aim in the current study was to examine the safety and initial efficacy across two low doses (a 
log-fold apart) ofIGF1, compared to placebo, with respect to LV function and structural remodeling 
post infarction in the setting of PPCI for STEMI. 
Methods 
Patient Selection 
Between November 2011 and July 2016 we performed a randomized, double-blind, placebo 
controlled multi-dose study of LD-IGF1 in STEMI patients who had undergone successful PPCI. All 
patients were treated at a single site (Cork University Hospital). We included STEMI (> 2mm ST 
elevation in two contiguous leads) patients, aged between 18-75 years, with significant LV 
dysfunction at angiography (LVEF≤40%). To ensure exclusion of aborted infarcts we excluded 
patients presenting within 2 hrs of symptoms and included those up to 12 hours of symptoms. The 
rationale for studying subjects up to 12 hours of symptoms related to preclinical data supporting 
cytoprotective effects of IGF1 on border-infract zone myocardium up to 12 hours post artery 
occlusion.We excluded all those patients with a previous history of structural heart disease, LV 
dysfunction, MI, CABG or PCI in addition to all major co-morbidities including significant prior renal 
and hepatic dysfunction(detailed exclusion criteria are outlined in Supplementary Figure 
1).Prespecified safety and efficacy endpoints are included in Supplementary Figure 2. 
The trial was approved by the Clinical Research Ethics Committee at Cork University Hospital and the 
Irish Medicines Board (since renamed the Health Products Regulatory Authority) and written 
informed consent was obtained from all patients. The authors are solely responsible for the design 
and conduct of this study, all study analyses, the drafting and editing of the paper and its final 
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contents. This trial was registered on clinical trials.gov NCT01438086 and was funded by the Health 
Research Board of Ireland HRB TRA/2010/20. 
Study design and procedures 
The design of the study is shown in Figure 1. Patients were randomly assigned, (with stratification for 
diabetes) [15]to each treatment group in a 1:1:1 ratio, using sequentially numbered sealed 
envelopes prepared by a statistician independent of the study.  We used a block size of 9 for the first 
18 subjects in each stratum and a 3 subject block size thereafter. LV angiography was done just after 
PCI. LVEF was assessed using a validated automated QVA system (Philips, NL) to determine LVEF as ≤ 
40%. Following successful PPCI and with TIMI 3 flow in the infarct related artery placebo containing 
0.9% sodium chloride, 1.5ng IGF1 (Mecasermin-Increlex) and 15ng IGF1 each diluted in 0.9% sodium 
chloride were prepared in 3 ml syringes. The method for reconstituting selected doses of IGF1 and 
placebo and the maintenance of double blinding and randomization to the point of administration 
down the coronary artery is outlined in supplementary methods section. Therapy was delivered via a 
perfusion catheter (Progreat, Terumo) with the catheter tip placed at the distal end of the stent used 
to treat the culprit lesion, and 3 mls of the assigned solution was injected slowly over 2 minutes. 
Coronary angiography was performed post injection to ensure artery patency.  
MRI Analysis 
We performed cardiac MRI (1.5T- Siemens) at 24 hours (range 18-36 hours) and 8 weeks post MI.  All 
scans were performed using commercially available MRI software, cardiac dedicated surface coils 
and ECG triggering. Global and regional LV function was assessed on breath-hold cine MRI in cardiac 
short, vertical and long axis. Infarct area was defined as a zone of bright signal on late enhanced 
images (approximately 10mins after 10-15mls intravenous bolus injection of gadolinium contrast) 
using inversion recovery gradient echo technique. 
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MRI datasets were analyzed on an off-line workstation (CAAS MRV 4.1, Pie Medical Imaging B.V., The 
Netherlands) by an independent MRI core laboratory (Cardialysis B.V., The Netherlands) unaware of 
treatment allocation. For assessment of global and regional LV function and calculation of LV mass, 
endocardial and epicardial borders were traced in end-diastolic and end-systolic short-axis slices. 
Papillary muscles were excluded from all analyses. The long axis correction method using the 2-
chamber and 4-charmber view was applied[6] and LV end-diastolic and end-systolic volumes (LVEDV 
and LVESV) were calculated. Infarct areas were defined as hyperintense signals on late-enhanced 
images with inversion-recovery gradient-echo sequences. The full-width-half-max method was used, 
and further correction with a slider and manual corrections were allowed. Microvascular obstruction 
was included in the infarct area.  
Statistical Analysis 
Statistical analysis was performed blinded to treatment assignment by staff at the statistical 
department of Cork University Clinical Research Facility. The sample size of 15 patients in each arm 
was based on an expected improvement in global LVEF (GLVEF) of 8 percentage points in the 
patients treated with 1.5 ng LD-IGF-1 (based on preclinical large animal data generated by our group 
[5]vs. a 2.2 percentage point increase in the placebo arm[16], with a shared SD of 5 percentage 
points. Under these assumptions and alpha of 0.05, we would detect the anticipated difference 
between the placebo and 1.5 ng LD-IGF-1 arms (15:15) with a power of 0.84; while the power would 
be 0.94 if comparing placebo to both treatment arms combined (15:30). Regarding adverse events, a 
sample size of 15 in a given arm would give a 95% confidence interval (CI) of 0 to 22% for any non-
observed events.  
Categorical data were described as counts and percentages, and continuous variables were 
described by their medians and IQRs. For estimates of adverse event rates, binomial 95% CIs were 
calculated using the Pearson-Klopper method. Mean outcome differences between each treatment 
arm and placebo were estimated with ANCOVA, adjusted for baseline outcome and diabetes status 
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at recruitment. We reported estimates, 95% CI, and the corresponding p-values from the two-sided 
test of the null hypothesis of no difference.  Models were estimated using complete case samples, 
thus assuming missing data were missing completely at random. Analyses were done on an 
intention-to-treat basis, or on a modified intention to treat basis in the presence of missing data 
(and for no other reason). All analyses were conducted using the R Project for Statistical Computing 
version 3.2 [17]. 
Results 
From 473 patients screened for eligibility 47 patients agreed to participate and were randomized. 
The enrolment pathway and trial profile is shown in Figure 2. The majority of the 426 patients 
excluded had systolic function that was greater than the threshold for study inclusion (LVEF<40%). 
46 patients completed the 8 week follow up. Baseline clinical characteristics did not statistically 
differ among treatment groups (Table 1). Median time from symptom onset to PCI was 4hours and 
from initiation of PCI to drug administration was approximately 70mins and did not vary among 
groups. The overall mean time from final balloon inflation to drug administration was 23.8 minutes. 
The per arm means were as follows: Placebo-19.6min; 1.5ngIGF1- 25.9min; 15ngIGF1- 25.6min. 
Although the mean times in the two active treatment arms were about 6 minutes greater than 
placebo the data were consistent with the null hypothesis in that there was no statistically 
significant difference between the groups (ANOVA p = 0.52).Use of thrombolysis was variable 
between treatment groups but TIMI flow prior to PCI was not significantly different statistically 
among groups and all patients enrolled had TIMI 3 flow after PCI (Table 1). 
 LV dysfunction (mean LVEF) on LV angiogram prior to drug administration was similar in all groups 
(Table 1).During hospital stay or at discharge there was also no significant difference in medications 
between groups and all patients adhered to their discharge medical regimen as determined at 30 
day phone follow up (Table1). 
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None of the pre-specified safety endpoints (hypoglycaemia, significant hypotension or tachy-
arrhythmia) occurred in the 1 first hour after study drug administration(Table 2).With respect to side 
effects previously reported for human growth hormone no patient (0/47) in the study reported jaw 
discomfort, arthralgia or persistent headache out to 30 days post drug administration. With respect 
to pre-specified clinical events in hospital there was no significant difference between groups (Table 
2). Moreover there was no significant difference in ischemic outcomes between groups out to 30 
day follow up (Table 2). 
There were 14 patients who experienced an arrhythmia (29% of 47 patients, 95% CI 17% to 45%), 
with four in the placebo arm, five in the 1.5ng IGF1 arm, and five in the 15ng IGF1 arm. Eight 
arrhythmias occurred on the day of the procedure, three at + 1 day, two at +2 days, and one at +3 
days. There was also one recurrent MI (+284 days) in the 15ng IGF1 arm, one recurrent severe 
ischemia (+93 days) in the 1.5ng IGF1 arm, and one death (+14 days) in the 15ng IGF1 arm (total 
sample 95%CIs for these singular events are 0 to 11%). There was no target vessel revascularisation 
(total sample 95%CIs for non-observed events are 0 to 7.5%), and there were no significant 
differences in the event rate across study arms out to 30 days (chi squared test p-value = 0.77). The 
1 patient death occurred at day 10 post MI and the patient died whilst sleeping at home 3 days after 
hospital discharge. The death was presumed due to ventricular arrhythmia and no autopsy was 
performed. 
Forty two patients had cardiac MRI performed at baseline and 8 weeks with 5 patients having no 
MRI data due to claustrophobia (4 patients) and 1 death (Figure 2). One additional patient had an 
MRI of insufficient quality due to incomplete breath hold because of pulmonary congestion during 
the baseline scan. Baseline and 8 week MRI data are presented for placebo, 1.5ng IGF1- and 15ng 
IGF1- patients on Figure 3 and Table 3.Forty one patients had complete MRI data suitable for GLVEF, 
LV volumes, mass, and stroke volume analysis both at baseline and 8 weeks. Eleven patients had 
scans that were not suitable for late gadolinium enhancement analysis all due to inadequate 
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prolonged breath-hold at the end of the scan at baseline (8 patients) and at 8 weeks (3 
patients).Thirty one patients had gadolinium enhancement suitable for infarct size analysis both at 
baseline and at 8 weeks. 
There was no apparent impact of treatment on the primary efficacy endpoint. Mean GLVEF at 24 hrs 
post-treatment was 39.4% (7.5 SD) in the placebo arm, and 41.2% (9.5) and 44.9% (8.0) in IGF1 1.5ng 
and 15ng arms respectively. This increased after 2 months in all three arms to 45.9% (5.8), 48.5% 
(13.5), and 50.2% (9.6) respectively (Figure 3). The difference in adjusted mean GLVEF compared to 
placebo was 1.76% (95% CI -3.35 to 6.87; p = 0.51) for 1.5 ng IGF1, and -0.90% (95% CI -6.09 to 4.29; 
p = 0.74) for 15 ng IGF1 . With reference to the assumptions underpinning the sample size 
calculation, GLVEF was more variable than expected, and there was a larger than anticipated 
improvement in GLVEF in the placebo arm.  
With regard to secondary efficacy endpoints compared with placebo, the 15ng IGF1  treatment was 
associated with a significant reduction in LV end-diastolic volume index (-16.38 ml/m2, 95% CI -29.30 
to -3.46; p = 0.018), LV mass index (-15.48 g/m2, 95% CI -23.97 to -7.00; p = 0.001) and stroke volume 
(-16.02 ml, 95% CI -28.49 to -3.56; p = 0.016). There were no apparent differences in any of these 
endpoints between the placebo and the IGF1 1.5ng arms (Table 3). 
There was a non-significant reduction in late contrast enhancement (LateCE) in the higher dose 15ng 
IGF1 - patients compared to the other two groups (95% CI -22.3 to 1.4, p=0.095, Table 3). Using the 
Benjamini-Hochberg procedure to adjust for multiple comparisons, by controlling the false discovery 
rate at 5%, all three secondary effects above remained significant for the higher dose IGF1 group 
when adjusted based on the ANCOVA p-values. 
Discussion 
This randomized double-blind placebo controlled clinical trial is the first to evaluate the safety and 
cardioprotective effects of low dose IGF1 in STEMI patients. While there were no safety concerns the 
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primary efficacy endpoint of greater enhancement in global LV systolic function was not met for 
either dose of IGF1 compared to placebo. In control and IGF1 treated subjects LVEF increased over 
the 2 month follow up consistent with prior revascularization trials using thombolytics or PCI[18-20]. 
With regard to secondary outcomes 15ng IGF1 significantly reduced LV volume (LVEDVI) in addition 
to attenuation of LV mass and stroke volume increases compared to 1.5ng dose IGF1 and placebo.  
The safety of both low doses of IGF1 in this trial is not surprising given that the concentrations of 
drug used was 100,000 fold less that doses previously proven safe to administer to normal human 
volunteer subjects (personal communication-Increlex manufacturer’s brochure). We were concerned 
specifically about acute (within the first hour of IC administration) glycemic, hypotensive and 
tachycardia side effects none of which occurred in the 32 subjects who received IGF1. As IGF1 has a 
half- life of 14 mins in the circulation we anticipated that side effects would most likely manifest 
early post injection. Moreover, there was no increase in later arrhythmias or any other major 
adverse cardiac events in the IGF1 treated subjects compared to placebo treated controls. We paid 
particular attention to hGH (which mediates effects through IGF1)-like side effects such as myalgia, 
arthralgia, headache and jaw pain all of which were not detected in any of the groups studied. There 
was one death in the higher IGF1 treated group (15 ng) but this patient died at day 10 post STEMI 
presumably of ventricular arrhythmia and it was felt that this did not relate to IGF1 treatment given 
the time of death and the known risk of ventricular arrhythmia in patients with LVEF <40% post 
STEMI. Thus this pilot study suggests that IGF1 at the doses administered in this trial is safe in the 
setting of acute STEMI. 
The rationale for evaluating the efficacy of intracoronary IGF1 in improving cardiac remodeling in 
patients undergoing myocardial infarction was based on experimental evidence supporting a key 
role of low dose IGF1 in initiating cardiomyocyte cytoprotection in the presence of reperfusion injury 
[5,9,10,14]. Briefly, in  a porcine model of 90 mins LAD occlusion  and  2 hours into reperfusion IGF 1 
at the lower dose range (1.5ng) used in this study improved cardiomyocyte survival and 2 month 
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remodeling of LV compared to placebo post experimental infarction [5]. Parallel signaling studies 
performed at 30 mins post IGF1 injection indicated specific phosphorylation of cognate IGF1  
receptor in cardiomyocytes in the infarct /border zone. Apoptotic assays at 24 hours indicated that 
cell death was effectively inhibited in the infarct border zone which abrogated later inflammatory 
and fibrotic changes in the infarcted heart [5]. 
Moreover, previous preclinical porcine work had shown that IGF1 in conditioned media at 
concentrations similar to the lower dose used in this trial was in part responsible for the 
cardioprotective effect of paracrine factors secreted from endothelial progenitor cells [21,22]. The 
timing of  IGF1 injection in patients was also based on this preclinical experience where early 
injection of conditioned media in the reperfusion phase post infarct injury successfully attenuated 
acute cardiomyocyte death, early inflammation and later scar formation and adverse LV dilatation 
post MI [22]. The reason why these promising preclinical data [5,22] were not predictive in the 
current human trial may relate to the complexity and heterogeneity of the human disease as well as 
reduced inter-subject variability in the porcine model used. 
Given the short half life of IGF1 [23] it is possible that some secondary efficacy effects seen in this 
trial may have been initiated early after injection. Experimental models have previously indicated 
that exogenous IGF1 delivered via the infarct-related artery enters at-risk myocardium, within 
minutes, most likely through permeable microvasculature in the infarct and border zones [5]. This 
event initiates a signaling cascade, in cardiomyocytes presenting IGF1 receptor, which includes 
Akt/PI3 kinase and GSK3β pro-survival pathways [5] the latter being implicated in regulation of 
crucial mitrochondrial permeability-transition pore function[5]. In this way early cytoprotection 
especially in the infarct border zone may act as a bulwark against further infarct expansion and 
maladaptive LV remodelling in the months post infarction. For instance, later cavity expansion is 
associated with compensatory hypertrophy increasing LV mass with attendant increases in stroke 
volume both of which are potentially indicators of maladaptive remodeling and may contribute to 
longterm heart failure [24,25].The strong trend to reduced infarct size in the 15ng IGF1 group would 
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support an early cytoprotective effect of IGF1 and is consistent with previous preclinical 
observations in multiple experimental models [5,9,10,14,21,22]. 
The major limitations of this pilot study include small sample size, variability in LVEF and other 
baseline characteristics especially pre-PCI thrombolysis TIMI 3 flow rate and the significant drop out 
rate of late gadolinium enhancement determination in 11 patients.  Together these limitations give 
insufficient power to determine the full clinical efficacy of intracoronary IGF1. The attained vs. 
expected % change in LVEF from baseline to 8 weeks was 8 (± 5) vs. 8.2 (± 7.5) for 15ng IGF1 dose 
and 2.2 (± 5) vs 6.5 (± 6.3) for placebo so LVEF as a parameter was more variable than expected, and 
the change in placebo was larger than expected. Thus future studies to test 15ng IGF1 vs placebo, 
based on the effect size and variance seen in the current trial would require 200 subjects in each 
arm with power = 0.8 and alpha = 0.05, based on t-test with common variance. There was variability 
in the DES stents used, and acute pharmacotherapy including thrombolytics, IIb/IIIa antagonists used 
although none of these parameters reached statistical significance in terms of group differences 
(Table 1). Despite this, it is likely that any future studies evaluating IGF1 should restrict patients to 
those with TIMI 0/1 flow on presentation and guidance on pharmacotherapy and stent treatment 
should aim to reduce inter-subject variability to a minimum. This current study reflected real world 
practice and left PPCI management of patients in catheterization lab to the discretion of the 
interventional cardiologist. 
Approximately 25% (11/42) of patients had gadolinium enhancement images unsuitable for analysis 
primarily due to difficulties in sustaining adequate breath-holding especially at the 24 hour baseline 
scan (8/11). In future studies it may therefore be beneficial to perform baseline scanning at 3 days 
rather than 24 hours post MI. Eight weeks was used as the follow up interval for repeat MRI based 
on previous large animal data. It may have been useful to look at a later timepoint of 4 months 
where non-infarct remodeling becomes more evident in terms of EDV and LV mass. We hope to 
capture some of this data in future analysis of 6 month echocardiography follow up (not included 
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here).Among patients missing any outcome data, there were no apparent differences from those 
with no missing data, with respect to the patient characteristics reported in Table 1. Moreover there 
were no appreciable differences when comparing patients who were missing any late CE data at 
baseline or 8 weeks (Supplementary Table 1). We cannot exclude the possibility of differences in 
unmeasured variables such as complexity of coronary artery disease or clinical risk scores. There was 
no statistically significant difference in peak troponins between treatment groups but temporal 
tracking of acute cardiomyocyte death(troponin release profile) was not specified as an efficacy 
endpoint and thus it is not clear whether IGF1 had any acute pro-survival effect. Given the previous 
safety profile of many log-fold higher doses of IGF1 in normal and IGF1 deficient human 
subjects(personal communication – Increlex manufacturers brochure) it is conceivable, that higher 
doses of IGF1 than used in this study would be safe and may have additional therapeutic potential. 
Moreover slow release IGF1 preparations or sequential dosing over time may extend the temporal 
window for therapeutic efficacy of this cytoprotective approach especially given that cardiomyocyte 
death is an ongoing process in the 24-72 hours post infarction[26]. Finally it is likely that increasing 
LVEF entry threshold to <45% may have enhanced enrolment and reduced the large number of 
screening failures in this trial. 
In conclusion, this study suggests that low dose IGF1 is safe when administered via the intracoronary 
route in the setting of STEMI undergoing PPCI. The failure to achieve a positive primary outcome 
added to several study limitations indicate that our secondary outcome data results can only be 
viewed as exploratory. Acknowledging design limitations  in the current study any future trial 
involving a larger number of patients should aim to reduce the variability in clinical presentation 
(TIMI flow, ischemic time) and MRI (LVEF, gadolinium drop-out) parameters observed in this study.  
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Figure 1 Study design 
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Figure 2. Trial Profile 
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Figure 3. Treatment effect of IGF1 and placebo on global LV ejection fraction (GLVEF) 
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TABLE 1. Baseline Characteristics 
Variable  
Total  
(n = 47) 
Placebo  
(n = 15) 
IGF1 1.5ng 
(n = 16) 
IGF1 15ng 
(n = 16) 
Test 
p-value 
Age (years)  59 [50, 66] 55 [51.5, 66] 57.5 [45.8, 65.5] 61.5 [52.2, 65.2] 0.78 
Sex  
    
0.57 
Male  37 (78.7%) 11 (73.3%) 12 (75%) 14 (87.5%)  
Female  10 (21.3%) 4 (26.7%) 4 (25%) 2 (12.5%)  
Smoking  
    
0.88 
0  11 (23.4%) 3 (20%) 3 (18.8%) 5 (31.2%)  
1  10 (21.3%) 4 (26.7%) 3 (18.8%) 3 (18.8%)  
2  26 (55.3%) 8 (53.3%) 10 (62.5%) 8 (50%)  
Hypertension  
    
0.97 
No  27 (57.4%) 9 (60%) 9 (56.2%) 9 (56.2%)  
Yes  20 (42.6%) 6 (40%) 7 (43.8%) 7 (43.8%)  
Dyslipidemia  
    
0.11 
No  37 (78.7%) 14 (93.3%) 10 (62.5%) 13 (81.2%)  
Yes  10 (21.3%) 1 (6.7%) 6 (37.5%) 3 (18.8%)  
Diabetes  
    
0.32 
No  44 (93.6%) 13 (86.7%) 16 (100%) 15 (93.8%)  
Yes  3 (6.4%) 2 (13.3%) 0 (0%) 1 (6.2%)  
Family history of  
cardiac disease 
 
    
0.05 
No  30 (68.2%) 12 (80%) 6 (42.9%) 12 (80%)  
Yes  14 (31.8%) 3 (20%) 8 (57.1%) 3 (20%)  
SBP (mmHg)  118 [106, 126.5] 128 [108.5, 142.5] 118 [103.8, 124.2] 113.5 [104.5, 119.2] 0.17 
DBP (mmHg)  75 [67, 84.5] 76 [70.5, 86.5] 73.5 [70, 84.5] 72.5 [60, 81.5] 0.51 
Heart rate (bpm)  84 [72.5, 94.5] 85 [76.5, 97] 82 [70.8, 91.8] 83.5 [74.5, 90] 0.46 
Height (cm)  172.7 [167, 179] 170.2 [168.5, 180.5] 170 [163, 174.8] 174.9 [172, 178.5] 0.18 
Weight (kg)  76.2 [69.9, 90] 71.1 [62.5, 92.7] 75.5 [66.5, 82.1] 81.2 [75.2, 90] 0.25 
BMI (kg/m
2
)  25.4 [22.8, 28.5] 23 [21.3, 28.5] 24.7 [23.1, 28.4] 26 [25.3, 28.9] 0.4 
TIMI flow prior 
to PCI 
 
    
0.11 
0  23 (50%) 10 (66.7%) 9 (60%) 4 (25%)  
1  4 (8.7%) 2 (13.3%) 0 (0%) 2 (12.5%)  
2  6 (13%) 2 (13.3%) 1 (6.7%) 3 (18.8%)  
3  13 (28.3%) 1 (6.7%) 5 (33.3%) 7 (43.8%)  
Infarct related 
artery 
 
    
0.34 
LAD  46 (97.9%) 14 (93.3%) 16 (100%) 16 (100%)  
LCx  1 (2.1%) 1 (6.7%) 0 (0%) 0 (0%)  
Thrombolysis 
prior to PCI 
 
    
0.23 
No  42 (89.4%) 15 (100%) 13 (81.2%) 14 (87.5%)  
Yes  5 (10.6%) 0 (0%) 3 (18.8%) 2 (12.5%)  
Post PCI LVEF  37.1 [33.3, 38.9] 36.9 [34.5, 38.5] 35 [27.8, 38.4] 37.8 [35.3, 38.8] 0.39 
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TABLE 1. Baseline Characteristics(contd.) 
   
 
Variable  
Total  
(n = 47) 
Placebo  
(n = 15) 
IGF1 1.5ng 
(n = 16) 
IGF1 15ng 
(n = 16) 
Test 
p-value 
Stent Type  
    
0.83 
DES  33 (70.2%) 12 (80%) 10 (62.5%) 11 (68.8%)  
BMS  4 (8.5%) 1 (6.7%) 2 (12.5%) 1 (6.2%)  
Bioabsorb-DES  10 (21.3%) 2 (13.3%) 4 (25%) 4 (25%)  
Baseline KILLIP  
    
0.21 
1  40 (87%) 13 (92.9%) 15 (93.8%) 12 (75%)  
2  6 (13%) 1 (7.1%) 1 (6.2%) 4 (25%)  
Peak troponin T (HS-ng/L) post PCI  5790 [3109, 8577] 
6183 [4174, 
8940] 
5900 [3884, 
9212] 
5389 [1876, 
7993] 
0.87 
Ischemia to PCI (min)  255 [200, 399] 240 [209, 323] 254 [222, 414] 279 [181, 451] 0.83 
Time from start of PCI to drug  
administration (min) 
 71 [57, 86] 62 [57.5, 79] 76.5 [57.5, 93.5] 79 [55, 87.2] 0.7 
 
Medications 
      
Antiplatelet  
    
 
ASA  47 (100%) 15 (100%) 16 (100%) 16 (100%) - 
Clopidogrel  18 (38.3%) 9 (60%) 3 (18.8%) 6 (37.5%) 0.06 
Prasugrel  16 (34%) 3 (20%) 8 (50%) 5 (31.2%) 0.2 
Ticagrelor  13 (29.8%) 3 (20%) 5 (31.2%) 5(31.2%) 0.72 
GPIIb/IIIa Antagonist  26 (56.5%) 8 (53.3%) 8 (53.3%) 10 (62.5%) 0.84 
2° Prevention  
    
 
Beta Blocker  47 (100%) 15 (100%) 16 (100%) 16 (100%) - 
Statin  47 (100%) 15 (100%) 16 (100%) 16 (100%) - 
Heart failure  
    
 
ACEI  42 (89.4%) 14 (93.3%) 13 (81.2%) 15 (93.8%) 0.43 
Aldosterone antagonist  17 (36.2%) 5 (33.3%) 5 (31.2%) 7 (43.8%) 0.73 
NYHA at discharge  
    
0.94 
1 
 
28 (59.6%) 9 (60%) 10 (62.5%) 9 (56.2%) 
 
2 
 
19 (40.4%) 6 (40%) 6 (37.5%) 7 (43.8%) 
 
LAD-Left anterior decending; LCx-Left circumflex; DES-Drug eluting stent; BMS-Bare metal stent; 
Bioabsorb-DES-Bioabsorable drug eluting stent. 
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There were no significant differences in the pre-specified safety event rates across study arms out 
to 30 days (chi squared test p-value = 0.77) 
  
TABLE 2.  Safety Endpoints  
 
  
 
 
Placebo IGF-1 (1.5ng) IGF-1  (15ng) 
 
n= 15 n= 16 n= 16 
Hemodynamic and blood glucose parameters    
 Hypotension 0 0 0 
Tachycardia 0 0 0 
Hypoglycemia 0 0 0 
Arrhythmias in the first 24 hours    
 Supraventricular Tachycardia 0 0 0 
Atrial Fibrillation  2 1 2 
Atrial Flutter  0 0 0 
Ventricular Tachycardia  0 0 0 
Non Sustained Ventricular Tachycardia  1 2 1 
Ventricular Fibrillation  0 0 0 
Arrhythmias during rest of hospital admission    
 Supraventricular Tachycardia 0 0 0 
Atrial Fibrillation  2 0 2 
Atrial Flutter  0 0 0 
Ventricular Tachycardia  1 0 0 
Non Sustained Ventricular tachycardia  0 0 0 
Ventricular Fibrillation  0 0 0 
Subacute Ischaemic Outcomes to 30 Days    
 Death 0 0 1 
Recurrent MI 0 0 0 
Repeat Revascularization IRA 0 0 0 
Heart Failure  0 0 0 
Stroke  0 0 0 
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TABLE 3.  Secondary efficacy endpoints 
 
 Baseline 8 Weeks Change ANCOVA 
 n Mean (SD) n Mean (SD) n 
Mean 
(SD) 
Estimate* 95%CI p 
LVEDV Index 
(ml/m2) 
         
Placebo 14 96 (16.2) 14 
114.5 
(20.6) 
14 
18.5 
(14.2)  
ref 
 
IGF1 1.5 ng 13 98.6 (17.3) 15 
105.1 
(22.4) 
13 9.1 (18) -10.251 
(-23.495 to 
2.992) 
0.138 
IGF1 15 ng 15 93.6 (9.7) 14 95 (24) 14 2.3 (18.9) -16.383 
(-29.304 to -
3.462) 
0.018 
LVESV Index 
(ml/m2) 
         
Placebo 14 58.7 (15) 14 62.2 (14.6) 14 3.6 (10.3) 
 
ref 
 
IGF1 1.5 ng 13 58.8 (17.3) 15 55.4 (21.5) 13 -2.6 (15.5) -6.594 (-16.85 to 3.663) 0.216 
IGF1 15 ng 15 51.8 (10.4) 14 49.5 (19.2) 14 -1.2 (13.4) -5.351 
(-15.611 to 
4.908) 
0.313 
LV Mass Index 
(g/m2) 
         
Placebo 10 85.8 (17) 12 85 (14.8) 9 0.5 (8.6) 
 
ref 
 
IGF1 1.5 ng 9 93 (17.1) 12 90.8 (7.2) 8 -2 (13.4) -1.083 
(-10.663 to 
8.498) 
0.827 
IGF1 15 ng 15 92.5 (19.9) 13 75.9 (18.4) 13 -17 (13.4) -15.484 
(-23.969 to -
6.998) 
0.001 
Stroke Volume (ml)          
Placebo 14 71.4 (20.3) 14 99.9 (26.1) 14 
28.4 
(17.8)  
ref 
 
IGF1 1.5 ng 13 74.2 (17.4) 15 92 (27) 13 
21.6 
(17.2) 
-7.801 
(-20.123 to 
4.521) 
0.223 
IGF1 15 ng 15 83.6 (15.7) 14 94.8 (14.9) 14 
10.9 
(14.1) 
-16.024 (-28.487 to -3.56) 0.016 
Late CE          
Placebo 10 56.2 (29) 12 49.1 (19.3) 9 
-12.5 
(20.4)  
ref 
 
IGF1 1.5 ng 10 59.2 (34.3) 12 47.4 (22.4) 9 
-12.4 
(21.2) 
-1.089 
(-14.022 to 
11.845) 
0.87 
IGF1 15 ng 15 56.8 (48.7) 13 34.5 (29.6) 13 
-18.2 
(26.2) 
-10.448 
(-22.254 to 
1.359) 
0.095 
          
          
          
          
* Expressed as differences (vs. Placebo) in adjusted means (ANCOVA, adjusted for baseline outcome and 
diabetes status) with corresponding 95% Cis and p-value from the two sided test of no difference. 
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